Compare Hormel Foods Corp (HRL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Hormel Foods Corp trades at $20.05 (market cap $10.90B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Hormel Foods Corp is the larger of the two by market cap, and Hormel Foods Corp pays a 5.91% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HRL | SYRE | |
|---|---|---|
Market Cap | $10.90B | $7.35B |
Volume | 5,843,624 | 1,624,631 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $108.92 |
52-Week Low | $19.19 | $22.18 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $12.89B | $6.35B |
Dividend Yield | 5.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.21, down 0.47% with a bearish technical outlook. The stock shows mixed fundamentals with declining net margins (2.82% in 2026) but consistent earnings beats and a $1.06B Brakebush acquisition to expand foodservice presence. Valuation metrics include a P/E of 30.98 and P/S of 0.87, while analyst consensus is cautious with 20% buy ratings.
Investment outlook balances dividend stability (60-year growth streak) against margin pressures and acquisition integration risks. The consensus price target of $25 offers 30% upside, but weak technicals and shrinking dividend raises warrant caution. Key catalysts include Brakebush synergies and foodservice growth execution.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
